Seraph-100 Microbind Affinity Blood Filter Flow Driven by the Extracorporeal Membrane Oxygenation Circuit in...

Area of Science:

• Critical Care Medicine
• Biomedical Engineering
• Infectious Disease Control

Background:

• The Seraph-100 Microbind Affinity Blood Filter is a novel extracorporeal therapy for removing blood-borne pathogens.
• Therapeutic efficacy of Seraph-100 requires specific blood flow rates, typically achieved via dialysis machines.
• Septic patients on extracorporeal membrane oxygenation (ECMO) may receive Seraph-100 therapy via the ECMO circuit, but data on flow rates is limited.

Purpose of the Study:

• To evaluate the feasibility and efficacy of connecting the Seraph-100 filter directly to an ECMO circuit.
• To determine if ECMO pump-driven flow through the Seraph-100 filter achieves therapeutic rates.
• To assess the impact of integrating the Seraph-100 circuit on ECMO system dynamics.

Main Methods:

• A swine model was used to configure and test the Seraph-100 circuit connected in parallel to the ECMO circuit.
• Seraph-100 blood flow rates were measured at varying ECMO blood flow rates (1.5 L/min to 5 L/min).
• Changes in ECMO revolutions per minute (RPM) and venous pressure were monitored.

Main Results:

• Seraph-100 flows ranged from an average of 137.27 ml/min at 1.5 L/min ECMO flow to 356.50 ml/min at 5 L/min ECMO flow.
• Integrating the Seraph-100 circuit increased ECMO RPM by 31.2 (p <0.05) and decreased venous pressure by -3.47 mmHg (p <0.05).
• These adjustments maintained target ECMO blood flow, indicating feasibility.

Conclusions:

• Directly connecting the Seraph-100 filter to an ECMO circuit is feasible.
• The ECMO pump can effectively drive blood flow through the Seraph-100 filter at rates adequate for clinical therapy.
• This integration strategy results in minimal alterations to ECMO system dynamics, supporting its use in critical care settings.